Last week, the Department of Labor’s Employee Benefits Security Administration released a rule requiring PBMs and their affiliated brokers and consultants to disclose the fees and compensation they receive, so employers can negotiate contracts and seek lower prescription drug costs for their customers. The agency projected the rule would lower prescription drug costs by up to $22 billion over 10 years.
Additionally, the final rule provides important compliance-assistance information for all service providers to employer-sponsored group health plans, which are now required to report fees and compensation to group health plan fiduciaries in initial plan and semi-annual disclosures. It also allows the plan fiduciaries to audit the accuracy of the PBM disclosures and provides additional relief for plan fiduciaries if a PBM fails to meet its obligations.
The new rule complements provisions included in the Consolidated Appropriations Act of 2026 and follows an executive order by President Donald Trump, “Lowering Drug Prices Once Again Putting Americans First.” NCPA strongly supported both measures.
Read our full press release here.
